Published in Nature on April 29, 2015
Fasting-Mimicking Diet Reduces HO-1 to Promote T Cell-Mediated Tumor Cytotoxicity. Cancer Cell (2016) 2.24
Eradication of large established tumors in mice by combination immunotherapy that engages innate and adaptive immune responses. Nat Med (2016) 1.52
Systemic Immunity Is Required for Effective Cancer Immunotherapy. Cell (2017) 1.44
Targeting lymphoma with precision using semisynthetic anti-idiotype peptibodies. Proc Natl Acad Sci U S A (2016) 1.39
Functional Specialization of Skin Dendritic Cell Subsets in Regulating T Cell Responses. Front Immunol (2015) 0.92
Autoantibody-boosted T-cell reactivation in the target organ triggers manifestation of autoimmune CNS disease. Proc Natl Acad Sci U S A (2016) 0.85
Spatial distribution of B cells predicts prognosis in human pancreatic adenocarcinoma. Oncoimmunology (2015) 0.84
Developing multi-target therapeutics to fine-tune the evolutionary dynamics of the cancer ecosystem. Front Pharmacol (2015) 0.83
Cancer: Antibodies regulate antitumour immunity. Nature (2015) 0.80
Antibody engineering & therapeutics, the annual meeting of the antibody society December 7-10, 2015, San Diego, CA, USA. MAbs (2016) 0.78
Positive and negative functions of B lymphocytes in tumors. Oncotarget (2016) 0.77
Tumor-binding antibodies and tumor immunity. Oncotarget (2015) 0.75
Immunotherapy against metastatic bladder cancer by combined administration of granulocyte macrophage-colony stimulating factor and interleukin-2 surface modified MB49 bladder cancer stem cells vaccine. Cancer Med (2017) 0.75
B lymphocytes and cancer: a love-hate relationship. Trends Cancer (2016) 0.75
Fusions of Tumor-derived Endothelial Cells with Dendritic Cells Induces Antitumor Immunity. Sci Rep (2017) 0.75
Fcγ Receptors in Solid Organ Transplantation. Curr Transplant Rep (2016) 0.75
In vivo amelioration of endogenous antitumor autoantibodies via low-dose P4N through the LTA4H/activin A/BAFF pathway. Proc Natl Acad Sci U S A (2016) 0.75
Human blood myeloid and plasmacytoid dendritic cells cross activate each other and synergize in inducing NK cell cytotoxicity. Oncoimmunology (2016) 0.75
Immunotherapy: Put your coat on! Nat Rev Cancer (2015) 0.75
Toll-like receptor 3-induced immune response by poly(d,l-lactide-co-glycolide) nanoparticles for dendritic cell-based cancer immunotherapy. Int J Nanomedicine (2016) 0.75
Attribution of NKG2DL to the inhibition of early stage allogeneic tumors in mice. Oncotarget (2016) 0.75
A specific immune and lymphatic profile characterizes the pre-metastatic state of the sentinel lymph node in patients with early cervical cancer. Oncoimmunology (2017) 0.75
Akt and SHP-1 are DC-intrinsic checkpoints for tumor immunity. JCI Insight (2016) 0.75
Tertiary Lymphoid Structures: An Anti-tumor School for Adaptive Immune Cells and an Antibody Factory to Fight Cancer? Front Immunol (2017) 0.75
Trial watch: Dendritic cell-based anticancer immunotherapy. Oncoimmunology (2017) 0.75
Roles for Innate Immunity in Combination Immunotherapies. Cancer Res (2017) 0.75
Immunity, inflammation, and cancer. Cell (2010) 28.27
Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science (2011) 15.79
Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell (2012) 8.71
Braf(V600E) cooperates with Pten loss to induce metastatic melanoma. Nat Genet (2009) 7.81
Natural innate and adaptive immunity to cancer. Annu Rev Immunol (2011) 7.09
Divergent immunoglobulin g subclass activity through selective Fc receptor binding. Science (2005) 6.48
De novo carcinogenesis promoted by chronic inflammation is B lymphocyte dependent. Cancer Cell (2005) 5.79
Fcgamma receptor-mediated induction of dendritic cell maturation and major histocompatibility complex class I-restricted antigen presentation after immune complex internalization. J Exp Med (1999) 5.55
Neutralizing tumor-promoting chronic inflammation: a magic bullet? Science (2013) 3.91
FcRgamma activation regulates inflammation-associated squamous carcinogenesis. Cancer Cell (2010) 3.80
p53 Antibodies in the sera of patients with various types of cancer: a review. Cancer Res (2000) 3.31
Haematopoietic cell transplantation as immunotherapy. Nature (2001) 2.88
B cells inhibit induction of T cell-dependent tumor immunity. Nat Med (1998) 2.50
Fc receptors are required in passive and active immunity to melanoma. Proc Natl Acad Sci U S A (1998) 2.50
Reversing lipopolysaccharide toxicity by ligating the macrophage Fc gamma receptors. J Immunol (2001) 2.49
Immune complex-mediated antigen presentation induces tumor immunity. J Clin Invest (2002) 2.13
B cells are required for optimal CD4+ and CD8+ T cell tumor immunity: therapeutic B cell depletion enhances B16 melanoma growth in mice. J Immunol (2010) 1.77
Immunogenicity of premalignant lesions is the primary cause of general cytotoxic T lymphocyte unresponsiveness. J Exp Med (2008) 1.70
Allogeneic lymphocytes induce tumor regression of advanced metastatic breast cancer. J Clin Oncol (2004) 1.62
Circulating anti-MUC1 IgG antibodies as a favorable prognostic factor for pancreatic cancer. Int J Cancer (2003) 1.51
Development of an orthotopic model of invasive pancreatic cancer in an immunocompetent murine host. Clin Cancer Res (2010) 1.27
Cutaneous acute graft-versus-host disease to minor histocompatibility antigens in a murine model: histologic analysis and correlation to clinical disease. J Invest Dermatol (1986) 1.24
Immune complex-loaded dendritic cells are superior to soluble immune complexes as antitumor vaccine. J Immunol (2006) 1.19
Adoptive transfer of tumor reactive B cells confers host T-cell immunity and tumor regression. Clin Cancer Res (2011) 1.13
Antigen recognition and allogeneic tumor rejection in CD8+ TCR transgenic/RAG(-/-) mice. J Immunol (1997) 1.04
Humoral immune response to MUC1 and to the Thomsen-Friedenreich (TF) glycotope in patients with gastric cancer: relation to survival. Acta Oncol (2007) 1.02
Minor histocompatibility antigens: allo target molecules for tumor-specific immunotherapy. Cancer J (2004) 0.96
Association of positive serum anti-p53 antibodies with poor prognosis in bladder cancer patients. Int J Urol (2004) 0.90
Efficacy and safety of intravenous immunoglobulin in patients with metastatic melanoma. Ann N Y Acad Sci (2007) 0.83
IVIg to prevent tumor metastases (Review). Int J Oncol (2002) 0.80